Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 9/20 | 0.34 |
| ▸ | DRD3 | P35462 | 9/20 | 0.34 |
| ▸ | DRD2 | P14416 | 8/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017973 | 1.00 | CA12 (0.41) | CA12CA7CA14HTR2ADRD3 | |
| SCHEMBL12017965 | 1.00 | CA12 (0.41) | CA12CA7CA14HTR2ADRD3 | |
| SCHEMBL7705222 | 0.82 | INPP5A (0.37) | — | |
| SCHEMBL48337 | 0.82 | — | — | |
| SCHEMBL15836240 | 0.82 | CA12 (0.58) | CA12CA7CA14CA1PGR | |
| SCHEMBL19694135 | 0.82 | SMYD3 (0.40) | CA12CA7CA14HTR2ADRD3 | |
| SCHEMBL19694137 | 0.82 | SMYD3 (0.40) | CA12CA7CA14HTR2ADRD3 | |
| SCHEMBL8294594 | 0.81 | CA12 (0.42) | CA12CA7CA14HTR2ADRD3 | |
| SCHEMBL8201280 | 0.81 | CA12 (0.42) | CA12CA7CA14HTR2ADRD3 | |
| SCHEMBL15014471 | 0.81 | CA12 (0.42) | CA12CA7CA14HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| EP-4688776-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | Acerta Pharma B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA BV (NL) | 2025-11-27 | — | — | US | disclosed |
| US-20240335431-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA B.V. (NL) | 2024-10-10 | — | — | US | disclosed |
| WO-2024201240-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | ACERTA PHARMA B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| EP-0444549-B1 | Imidazopyridazines their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5145850-A | Antiasthmatic | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-09-08 | — | — | US | disclosed |
| EP-0444549-A1 | Imidazopyridazines their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | MEN1, PKD1, PKD2 | CA12 2284/4885CA7 2003/4885CA14 2320/4885 |
| US-20240335431-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | MEN1, PKD1, ADCYAP1R1 | CA12 3994/4885CA7 2601/4885CA14 4071/4885 |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | MEN1, PKD1, ADCYAP1R1 | CA12 3994/4885CA7 2601/4885CA14 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.